413 related articles for article (PubMed ID: 14718605)
1. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
2. Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Zhang Y; Hegen M; Xu J; Keith JC; Jin G; Du X; Cummons T; Sheppard BJ; Sun L; Zhu Y; Rao VR; Wang Q; Xu W; Cowling R; Nickerson-Nutter CL; Gibbons J; Skotnicki J; Lin LL; Levin J
Int Immunopharmacol; 2004 Dec; 4(14):1845-57. PubMed ID: 15531300
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alpha (TNF-alpha) converting enzyme contributes to production of TNF-alpha in synovial tissues from patients with rheumatoid arthritis.
Ohta S; Harigai M; Tanaka M; Kawaguchi Y; Sugiura T; Takagi K; Fukasawa C; Hara M; Kamatani N
J Rheumatol; 2001 Aug; 28(8):1756-63. PubMed ID: 11508576
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases.
Conway JG; Andrews RC; Beaudet B; Bickett DM; Boncek V; Brodie TA; Clark RL; Crumrine RC; Leenitzer MA; McDougald DL; Han B; Hedeen K; Lin P; Milla M; Moss M; Pink H; Rabinowitz MH; Tippin T; Scates PW; Selph J; Stimpson SA; Warner J; Becherer JD
J Pharmacol Exp Ther; 2001 Sep; 298(3):900-8. PubMed ID: 11504783
[TBL] [Abstract][Full Text] [Related]
5. Anti-arthritis effect of a novel quinazoline derivative through inhibiting production of TNF-α mediated by TNF-α converting enzyme in murine collagen-induced arthritis model.
Pu Y; Cao D; Xie C; Pei H; Li D; Tang M; Chen L
Biochem Biophys Res Commun; 2015 Jul; 462(4):288-93. PubMed ID: 25935488
[TBL] [Abstract][Full Text] [Related]
6. (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2'-isobutyl-2'-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.
Beck G; Bottomley G; Bradshaw D; Brewster M; Broadhurst M; Devos R; Hill C; Johnson W; Kim HJ; Kirtland S; Kneer J; Lad N; Mackenzie R; Martin R; Nixon J; Price G; Rodwell A; Rose F; Tang JP; Walter DS; Wilson K; Worth E
J Pharmacol Exp Ther; 2002 Jul; 302(1):390-6. PubMed ID: 12065742
[TBL] [Abstract][Full Text] [Related]
7. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis.
Thabet MM; Huizinga TW
Curr Opin Investig Drugs; 2006 Nov; 7(11):1014-9. PubMed ID: 17117591
[TBL] [Abstract][Full Text] [Related]
8. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
9. Effects of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in a model of intestinal reperfusion injury in mice.
Souza DG; Ferreira FL; Fagundes CT; Amaral FA; Vieira AT; Lisboa RA; Andrade MV; Trifilieff A; Teixeira MM
Eur J Pharmacol; 2007 Sep; 571(1):72-80. PubMed ID: 17619015
[TBL] [Abstract][Full Text] [Related]
10. Benzodiazepine inhibitors of the MMPs and TACE. Part 2.
Levin JI; Nelson FC; Delos Santos E; Du MT; MacEwan G; Chen JM; Ayral-Kaloustian S; Xu J; Jin G; Cummons T; Barone D
Bioorg Med Chem Lett; 2004 Aug; 14(16):4147-51. PubMed ID: 15261259
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a potent and selective inhibitor of tumor necrosis factor alpha-converting enzyme in rodents, dogs, chimpanzees, and humans.
Qian M; Bai SA; Brogdon B; Wu JT; Liu RQ; Covington MB; Vaddi K; Newton RC; Fossler MJ; Garner CE; Deng Y; Maduskuie T; Trzaskos J; Duan JJ; Decicco CP; Christ DD
Drug Metab Dispos; 2007 Oct; 35(10):1916-25. PubMed ID: 17656469
[TBL] [Abstract][Full Text] [Related]
12. Design strategies for the identification of MMP-13 and Tace inhibitors.
Skotnicki JS; DiGrandi MJ; Levin JI
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
[TBL] [Abstract][Full Text] [Related]
13. The role of cytokines in osteoarthritis pathophysiology.
Fernandes JC; Martel-Pelletier J; Pelletier JP
Biorheology; 2002; 39(1-2):237-46. PubMed ID: 12082286
[TBL] [Abstract][Full Text] [Related]
14. Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis.
Kunisch E; Gandesiri M; Fuhrmann R; Roth A; Winter R; Kinne RW
Ann Rheum Dis; 2007 Aug; 66(8):1043-51. PubMed ID: 17223661
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
Venkatesan AM; Davis JM; Grosu GT; Baker J; Zask A; Levin JI; Ellingboe J; Skotnicki JS; Dijoseph JF; Sung A; Jin G; Xu W; McCarthy DJ; Barone D
J Med Chem; 2004 Dec; 47(25):6255-69. PubMed ID: 15566296
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation.
Trifilieff A; Walker C; Keller T; Kottirsch G; Neumann U
Br J Pharmacol; 2002 Apr; 135(7):1655-64. PubMed ID: 11934805
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
18. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
19. Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis.
Tsuji F; Oki K; Okahara A; Suhara H; Yamanouchi T; Sasano M; Mita S; Horiuchi M
Cytokine; 2002 Mar; 17(6):294-300. PubMed ID: 12061836
[TBL] [Abstract][Full Text] [Related]
20. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
